UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 5, 2025
Creative Medical Technology Holdings, Inc. |
(Exact name of registrant as specified in its charter) |
Nevada |
| 000-53500 |
| 87-0622284 |
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (I.R.S. Employer Identification Number) |
211 E Osborn Road, Phoenix, AZ85012
(Address of principal executive offices)
(480) 399-2822
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, par value $0.001 per share | CELZ | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 5, 2025, the Company held a Special Meeting of Stockholders (the “Special Meeting”) to consider and vote on a proposal to approve the exercise in full of warrants to purchase an aggregate of 1,799,774 shares of the Company’s common stock, issued by the Company on March 6, 2025 (the “Proposal”). The Proposal is described in more detail in the definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission on March 17, 2025. Stockholders holding an aggregate of 813,562 shares of common stock, representing 35.0% of the outstanding shares of the Company’s common stock as of the record date, and which constituted a quorum, were present in person or represented by proxy at the Special Meeting. The results of the voting for the Proposal, which was approved at the Special Meeting, are presented below.
For | Against | Abstain | Broker Non-Votes |
308,051 | 39,229 | 466,282 | N/A |
Item 9.01 Financial Statements and Exhibits.
(d) | Exhibits. |
|
|
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
2 |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Creative Medical Technology Holdings, Inc. |
| |
|
|
| |
Date: May 6, 2025 | By: | /s/ Timothy Warbington |
|
|
| Timothy Warbington, Chief Executive Officer |
|
3 |